<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03494725</url>
  </required_header>
  <id_info>
    <org_study_id>DU01-2017</org_study_id>
    <nct_id>NCT03494725</nct_id>
  </id_info>
  <brief_title>Stress &amp; Anxiety Dampening Effects of a Probiotic Supplement Compared to Placebo in Healthy Subjects</brief_title>
  <official_title>Proof-of-Concept &quot;Stress &amp; Anxiety Dampening Effects of Lpc-37&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daacro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DuPont Nutrition and Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daacro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess whether a 5 week intake of a probiotic (Lpc-37) can
      modulate stress and anxiety experienced by healthy subjects during and after an acute
      stressor compared to placebo. To measure stress and anxiety, markers of the
      hypothalamic-pituitary-adrenal (HPA) axis activity and questionnaires will be assessed
      before, during and after the Trier Social Stress Test (TSST). The results of this study
      indicate if the chosen study design is suitable to discover stress-related effects of
      probiotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total mass of microorganisms residing within the human intestine is approximately the
      same as that of the human brain. Of late, these &gt;1000 species and &gt;7000 strains have been
      described as the &quot;brain in our belly&quot; because of the essential role they play in
      physiological and psychological health and disease. The gut-brain axis describes the
      bidirectional communication that exists between the brain and the gut and the
      microbiota-gut-brain axis supports the role of the gut microbiome in this communication
      system. Emotional and routine daily life stress can disrupt digestive function, but
      increasing evidence indicates that the gut microbiota exert a profound influence on brain
      physiology, psychological responses and ultimately behavior.

      A plethora of literature to date, albeit majoritively preclinical, have demonstrated evidence
      to support the role of the gut microbiome in regulating stress-related changes in physiology,
      behavior and brain function.

      Stress is an individual process to deal with external and internal challenges that ranges
      from behavioral to molecular adaptations. The HPA axis and its release of stress hormones
      plays a major role in stress adaptation.

      The purpose of this clinical trial is to determine whether a single strain of bacteria
      derived from the species Lactobacillus paracasei (Lpc-37) can modulate stress experienced by
      healthy subjects exposed to the TSST measured by HPA axis activation markers and self-report
      questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the HR in response to the TSST</measure>
    <time_frame>Continuous measurement starting 20 minutes before the TSST and ending 20 minutes after the TSST after 5 weeks of product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on reduction of the increase of the heart rate (HR) in response to the TSST compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in pre and post treatment STAI-state scores</measure>
    <time_frame>Before and after 5 weeks of study product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of State-Trait-Anxiety-Inventory (STAI)-state scores compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre and post treatment PSS scores</measure>
    <time_frame>Before and after 5 weeks of study product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of Perceived Stress Scale (PSS) scores compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre and post treatment DASS depression scores</measure>
    <time_frame>Before and after 5 weeks of study product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of Depression Anxiety Stress Scale (DASS) depression scores compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre and post treatment DASS anxiety scores</measure>
    <time_frame>Before and after 5 weeks of study product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of DASS anxiety scores compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre and post treatment DASS stress scores</measure>
    <time_frame>Before and after 5 weeks of study product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of DASS stress scores compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre and post treatment BAI scores</measure>
    <time_frame>Before and after 5 weeks of study product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of Beck Anxiety Inventory (BAI) scores compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre and post treatment VAS stress perception scores</measure>
    <time_frame>Before and after 5 weeks of study product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of Visual Analog Scale (VAS) stress perception scores compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre and post treatment VAS anxiety scores</measure>
    <time_frame>Before and after 5 weeks of study product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of VAS anxiety scores compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre and post treatment VAS insecurity scores</measure>
    <time_frame>Before and after 5 weeks of study product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of VAS insecurity scores compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre and post treatment VAS exhaustion scores</measure>
    <time_frame>Before and after 5 weeks of study product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of VAS exhaustion scores compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre and post treatment systolic BP</measure>
    <time_frame>Before and after 5 weeks of study product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of systolic blood pressure (BP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre and post treatment diastolic BP</measure>
    <time_frame>Before and after 5 weeks of study product intake.</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of diastolic BP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of STAI-state scores in response to the TSST</measure>
    <time_frame>10 minutes before the TSST and 1 minute after the TSST after 5 weeks of study product intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on reduction of the increase of STAI-state scores in response to the TSST compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of systolic BP in response to the TSST</measure>
    <time_frame>3 minutes before the TSST and 1 minute after the TSST after 5 weeks of study product intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on reduction of the increase of the systolic BP in response to the TSST compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of diastolic BP in response to the TSST</measure>
    <time_frame>3 minutes before the TSST and 1 minute after the TSST after 5 weeks of study product intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on reduction of the increase of the diastolic BP in response to the TSST compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VAS stress perception scores in response to the TSST</measure>
    <time_frame>10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on reduction of the increase of VAS stress perception scores in response to the TSST compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VAS anxiety scores in response to the TSST</measure>
    <time_frame>10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on reduction of the increase of VAS anxiety scores in response to the TSST compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VAS insecurity scores in response to the TSST</measure>
    <time_frame>10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on reduction of the increase of VAS insecurity scores in response to the TSST compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VAS exhaustion scores in response to the TSST</measure>
    <time_frame>10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on reduction of the increase of VAS exhaustion scores in response to the TSST compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of salivary cortisol in response to the TSST</measure>
    <time_frame>1 minute before the TSST and 1, 10, 20, 30 and 45 minutes after the TSST after 5 weeks of study product intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on reduction of the increase of salivary cortisol in response to the TSST compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of sAA in response to the TSST</measure>
    <time_frame>1 minute before the TSST and 1, 10, 20, 30 and 45 minutes after the TSST after 5 weeks of study product intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on reduction of the increase of salivary Alpha-Amylase (sAA) in response to the TSST compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of sleep duration over the course of the treatment</measure>
    <time_frame>Daily for 2 weeks before treatment intake and 5 weeks during treatment intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the increase of sleep duration over the course of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of sleep related recovery scores over the course of the treatment</measure>
    <time_frame>Daily for 2 weeks before treatment intake and 5 weeks during treatment intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the increase of sleep related recovery scores over the course of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of reported number of sleep disruptions over the course of the treatment</measure>
    <time_frame>Daily for 2 weeks before treatment intake and 5 weeks during treatment intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the decrease of reported number of sleep disruptions over the course of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of perceived health status scores over the course of the treatment</measure>
    <time_frame>Daily for 2 weeks before treatment intake and 5 weeks during treatment intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the increase of perceived health status scores over the course of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of mood scale scores over the course of the treatment</measure>
    <time_frame>Daily for 2 weeks before treatment intake and 5 weeks during treatment intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the increase of mood scale scores over the course of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of perceived productivity scores over the course of the treatment</measure>
    <time_frame>Daily for 2 weeks before treatment intake and 5 weeks during treatment intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the increase of perceived productivity scores over the course of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the difference of CAR AUCg measures before and after treatment</measure>
    <time_frame>3 and 2 days before first product intake and 2 and 1 day before last product intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of the difference of Cortisol Awakening Response (CAR) area under the curve with respect to the ground (AUCg) values to the respective mean before and after 5 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the difference of CAR AUCi measures before and after treatment</measure>
    <time_frame>3 and 2 days before first product intake and 2 and 1 day before last product intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of the difference of CAR area under the curve with respect to the increase (AUCi) values to the respective mean before and after 5 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the difference of CAR total increase measures before and after treatment</measure>
    <time_frame>3 and 2 days before first product intake and 2 and 1 day before last product intake</time_frame>
    <description>Efficacy of the intake of Lpc-37 on the reduction of the difference of CAR total increase values to the respective mean before and after 5 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Healthy</condition>
  <condition>Stress, Psychological</condition>
  <arm_group>
    <arm_group_label>Lpc-37</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactobacillus paracasei Lpc-37
1x 1 capsule in the morning for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule manufactured to mimic Lpc-37 capsule
1x 1 capsule in the morning for 5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lpc-37</intervention_name>
    <description>Lactobacillus paracasei Lpc-37 at 1 x 10^10 colony forming units (CFU) per day, Microcrystalline cellulose, Magnesium stearate, silicon dioxide</description>
    <arm_group_label>Lpc-37</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Microcrystalline cellulose, Magnesium stearate, silicon dioxide</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary, written, informed consent to participate in the study

          -  Male or female aged between 18-45 years (inclusive)

          -  Body mass index (BMI) between 18.5 - 29.9 kg/m2

          -  Medical examination at baseline indicates they are healthy in the opinion of the
             investigator

          -  Ability of the participant (in the Principal Investigator's opinion) to comprehend the
             full nature and purpose of the study including possible risks and side effects

          -  Agreement to comply with the protocol and study restrictions

          -  Available for all study visits

          -  Females of child-bearing potential required to provide a negative urine pregnancy test
             and to use contraceptives

          -  Easy access to internet

        Exclusion Criteria:

          -  Self-reported diagnosis of one or more Diagnostic and Statistical Manual of Mental
             Disorders (DSM)-IV axis 1 disorder(s), including but not limited to current major
             depression, anxiety disorder, bipolar spectrum disorder or schizophrenia

          -  Have a significant acute or chronic coexisting illness (cardiovascular,
             gastrointestinal (irritable bowel syndrome (IBS), inflammatory bowel disease (IBD)),
             immunological, metabolic, neurodevelopmental or any condition which contraindicates,
             in the Investigator's judgement, entry to the study

          -  Currently taking (from day of screening onwards) or have previously taken (last 4
             weeks prior to screening) psychoactive medication (anxiolytics, sedatives, hypnotics,
             anti-psychotics, anti-depressants, anti-convulsants, centrally acting corticosteroids,
             opioid pain relievers)

          -  Currently taking (from day of screening onwards) medication or dietary supplements
             that the Investigator believes would interfere with the objectives of the study, pose
             a safety risk or confound the interpretation of the study results (e.g. melatonin,
             omega-3 dietary supplements, non-steroidal anti-inflammatory drugs (NSAIDS),
             over-the-counter (OTC) sleep medication (not categorized as sedatives, hypnotics or
             anti-depressants), anti-coagulants, proton pump inhibitors, anti-histamines,
             pseudoephedrine, cortisone, beta-blockers)

          -  Recent (within last 4 weeks prior to screening) or ongoing antibiotic therapy during
             the intervention period

          -  Daily consumption of concentrated sources of probiotics and/or prebiotics within 2
             weeks of screening and throughout the intervention period other than the provided
             study products (e.g., probiotic/prebiotic tablets, capsules, drops or powders)

          -  Pregnant or lactating female, or pregnancy planned during intervention period

          -  Not fluent in German

          -  Have self-reported dyslexia

          -  History of alcohol, drug, or medication abuse

          -  Self-declared illicit drug users (including cannabis and cocaine) for 3 weeks prior to
             screening and during the intervention period

          -  Contraindication to any substance in the investigational product

          -  Hypertension (systolic ≥ 140 mmHg, diastolic ≥ 90 mmHg)

          -  Known hyper- or hypothyroidism unless treated and under control (stable for more than
             3 months)

          -  Subjects having previously participated in the TSST

          -  Smoking &gt; 5 cigarettes/day

          -  Employee of the sponsor or contract research organization (CRO)

          -  Participation in another study with any investigational product within 60 days of
             screening and during the intervention period

          -  Investigator believes that the participant may be uncooperative and/or noncompliant
             and should therefore not participate in the study

          -  Participant under administrative or legal supervision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juliane Hellhammer, PhD</last_name>
    <phone>+496519120494</phone>
    <email>info@daacro.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>daacro GmbH &amp; Co. KG</name>
      <address>
        <city>Trier</city>
        <state>Rhineland-Palatinate</state>
        <zip>54296</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliane Hellhammer, PhD</last_name>
      <phone>+496519120494</phone>
      <email>hellhammer@daacro.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.daacro.de</url>
    <description>daacro homepage</description>
  </link>
  <reference>
    <citation>Bailey MT, Coe CL. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev Psychobiol. 1999 Sep;35(2):146-55.</citation>
    <PMID>10461128</PMID>
  </reference>
  <reference>
    <citation>Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M. Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation. Brain Behav Immun. 2011 Mar;25(3):397-407. doi: 10.1016/j.bbi.2010.10.023. Epub 2010 Oct 30.</citation>
    <PMID>21040780</PMID>
  </reference>
  <reference>
    <citation>Bailey MT, Lubach GR, Coe CL. Prenatal stress alters bacterial colonization of the gut in infant monkeys. J Pediatr Gastroenterol Nutr. 2004 Apr;38(4):414-21.</citation>
    <PMID>15085020</PMID>
  </reference>
  <reference>
    <citation>Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett P, Macri J, McCoy KD, Verdu EF, Collins SM. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology. 2011 Aug;141(2):599-609, 609.e1-3. doi: 10.1053/j.gastro.2011.04.052. Epub 2011 Apr 30.</citation>
    <PMID>21683077</PMID>
  </reference>
  <reference>
    <citation>Bercik P, Park AJ, Sinclair D, Khoshdel A, Lu J, Huang X, Deng Y, Blennerhassett PA, Fahnestock M, Moine D, Berger B, Huizinga JD, Kunze W, McLean PG, Bergonzelli GE, Collins SM, Verdu EF. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil. 2011 Dec;23(12):1132-9. doi: 10.1111/j.1365-2982.2011.01796.x. Epub 2011 Oct 11.</citation>
    <PMID>21988661</PMID>
  </reference>
  <reference>
    <citation>Bharwani A, Mian MF, Foster JA, Surette MG, Bienenstock J, Forsythe P. Structural &amp; functional consequences of chronic psychosocial stress on the microbiome &amp; host. Psychoneuroendocrinology. 2016 Jan;63:217-27. doi: 10.1016/j.psyneuen.2015.10.001. Epub 2015 Oct 9.</citation>
    <PMID>26479188</PMID>
  </reference>
  <reference>
    <citation>Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16050-5. doi: 10.1073/pnas.1102999108. Epub 2011 Aug 29.</citation>
    <PMID>21876150</PMID>
  </reference>
  <reference>
    <citation>Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, Dinan TG, Cryan JF. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2013 Jun;18(6):666-73. doi: 10.1038/mp.2012.77. Epub 2012 Jun 12.</citation>
    <PMID>22688187</PMID>
  </reference>
  <reference>
    <citation>Daulatzai MA. Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia. Neurochem Res. 2014 Apr;39(4):624-44. doi: 10.1007/s11064-014-1266-6. Epub 2014 Mar 4. Review.</citation>
    <PMID>24590859</PMID>
  </reference>
  <reference>
    <citation>Dallman, M. F., &amp; Hellhammer, D. (2011). Regulation of the hypothalamo-pituitaryadrenal axis, chronic stress, and energy: the role of brain networks. The handbook of stress science: Biology, psychology, and health, 11-36.</citation>
  </reference>
  <reference>
    <citation>De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, Bäckhed F, Mithieux G. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014 Jan 16;156(1-2):84-96. doi: 10.1016/j.cell.2013.12.016. Epub 2014 Jan 9.</citation>
    <PMID>24412651</PMID>
  </reference>
  <reference>
    <citation>Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. J Psychiatr Res. 2008 Dec;43(2):164-74. doi: 10.1016/j.jpsychires.2008.03.009. Epub 2008 May 5.</citation>
    <PMID>18456279</PMID>
  </reference>
  <reference>
    <citation>Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience. 2010 Nov 10;170(4):1179-88. doi: 10.1016/j.neuroscience.2010.08.005. Epub 2010 Aug 6.</citation>
    <PMID>20696216</PMID>
  </reference>
  <reference>
    <citation>Dickerson SS, Kemeny ME. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. Psychol Bull. 2004 May;130(3):355-91.</citation>
    <PMID>15122924</PMID>
  </reference>
  <reference>
    <citation>Dinan TG, Cryan JF. Mood by microbe: towards clinical translation. Genome Med. 2016 Apr 6;8(1):36. doi: 10.1186/s13073-016-0292-1. Review.</citation>
    <PMID>27048547</PMID>
  </reference>
  <reference>
    <citation>Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biol Psychiatry. 2013 Nov 15;74(10):720-6. doi: 10.1016/j.biopsych.2013.05.001. Epub 2013 Jun 10. Review.</citation>
    <PMID>23759244</PMID>
  </reference>
  <reference>
    <citation>Dinan TG, Stilling RM, Stanton C, Cryan JF. Collective unconscious: how gut microbes shape human behavior. J Psychiatr Res. 2015 Apr;63:1-9. doi: 10.1016/j.jpsychires.2015.02.021. Epub 2015 Mar 3. Review.</citation>
    <PMID>25772005</PMID>
  </reference>
  <reference>
    <citation>Foster JA, Lyte M, Meyer E, Cryan JF. Gut Microbiota and Brain Function: An Evolving Field in Neuroscience. Int J Neuropsychopharmacol. 2016 Apr 29;19(5). pii: pyv114. doi: 10.1093/ijnp/pyv114. Print 2016 May.</citation>
    <PMID>26438800</PMID>
  </reference>
  <reference>
    <citation>Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013 May;36(5):305-12. doi: 10.1016/j.tins.2013.01.005. Epub 2013 Feb 4. Review.</citation>
    <PMID>23384445</PMID>
  </reference>
  <reference>
    <citation>Foster JA, Rinaman L, Cryan JF. Stress &amp; the gut-brain axis: Regulation by the microbiome. Neurobiol Stress. 2017 Mar 19;7:124-136. doi: 10.1016/j.ynstr.2017.03.001. eCollection 2017 Dec. Review.</citation>
    <PMID>29276734</PMID>
  </reference>
  <reference>
    <citation>Fries E, Dettenborn L, Kirschbaum C. The cortisol awakening response (CAR): facts and future directions. Int J Psychophysiol. 2009 Apr;72(1):67-73. doi: 10.1016/j.ijpsycho.2008.03.014. Epub 2008 Sep 30. Review.</citation>
    <PMID>18854200</PMID>
  </reference>
  <reference>
    <citation>Golubeva AV, Crampton S, Desbonnet L, Edge D, O'Sullivan O, Lomasney KW, Zhdanov AV, Crispie F, Moloney RD, Borre YE, Cotter PD, Hyland NP, O'Halloran KD, Dinan TG, O'Keeffe GW, Cryan JF. Prenatal stress-induced alterations in major physiological systems correlate with gut microbiota composition in adulthood. Psychoneuroendocrinology. 2015 Oct;60:58-74. doi: 10.1016/j.psyneuen.2015.06.002. Epub 2015 Jun 17.</citation>
    <PMID>26135201</PMID>
  </reference>
  <reference>
    <citation>Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):3047-52. doi: 10.1073/pnas.1010529108. Epub 2011 Jan 31.</citation>
    <PMID>21282636</PMID>
  </reference>
  <reference>
    <citation>Hellhammer DH, Wade S. Endocrine correlates of stress vulnerability. Psychother Psychosom. 1993;60(1):8-17. Review.</citation>
    <PMID>8234641</PMID>
  </reference>
  <reference>
    <citation>Holsboer F, Ising M. Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol. 2010;61:81-109, C1-11. doi: 10.1146/annurev.psych.093008.100321. Review.</citation>
    <PMID>19575614</PMID>
  </reference>
  <reference>
    <citation>Janak PH, Tye KM. From circuits to behaviour in the amygdala. Nature. 2015 Jan 15;517(7534):284-92. doi: 10.1038/nature14188. Review.</citation>
    <PMID>25592533</PMID>
  </reference>
  <reference>
    <citation>Jašarević E, Howerton CL, Howard CD, Bale TL. Alterations in the Vaginal Microbiome by Maternal Stress Are Associated With Metabolic Reprogramming of the Offspring Gut and Brain. Endocrinology. 2015 Sep;156(9):3265-76. doi: 10.1210/en.2015-1177. Epub 2015 Jun 16.</citation>
    <PMID>26079804</PMID>
  </reference>
  <reference>
    <citation>Kelly JR, Borre Y, O' Brien C, Patterson E, El Aidy S, Deane J, Kennedy PJ, Beers S, Scott K, Moloney G, Hoban AE, Scott L, Fitzgerald P, Ross P, Stanton C, Clarke G, Cryan JF, Dinan TG. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res. 2016 Nov;82:109-18. doi: 10.1016/j.jpsychires.2016.07.019. Epub 2016 Jul 25.</citation>
    <PMID>27491067</PMID>
  </reference>
  <reference>
    <citation>Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci. 2015 Oct 14;9:392. doi: 10.3389/fncel.2015.00392. eCollection 2015. Review.</citation>
    <PMID>26528128</PMID>
  </reference>
  <reference>
    <citation>Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993;28(1-2):76-81.</citation>
    <PMID>8255414</PMID>
  </reference>
  <reference>
    <citation>Kudielka BM, Wüst S. Human models in acute and chronic stress: assessing determinants of individual hypothalamus-pituitary-adrenal axis activity and reactivity. Stress. 2010 Jan;13(1):1-14. doi: 10.3109/10253890902874913. Review.</citation>
    <PMID>20105052</PMID>
  </reference>
  <reference>
    <citation>Luczynski P, McVey Neufeld KA, Oriach CS, Clarke G, Dinan TG, Cryan JF. Growing up in a Bubble: Using Germ-Free Animals to Assess the Influence of the Gut Microbiota on Brain and Behavior. Int J Neuropsychopharmacol. 2016 Aug 12;19(8). pii: pyw020. doi: 10.1093/ijnp/pyw020. Print 2016 Aug. Review.</citation>
    <PMID>26912607</PMID>
  </reference>
  <reference>
    <citation>Mackowiak PA. Recycling metchnikoff: probiotics, the intestinal microbiome and the quest for long life. Front Public Health. 2013 Nov 13;1:52. doi: 10.3389/fpubh.2013.00052. Review.</citation>
    <PMID>24350221</PMID>
  </reference>
  <reference>
    <citation>Marcos A, Wärnberg J, Nova E, Gómez S, Alvarez A, Alvarez R, Mateos JA, Cobo JM. The effect of milk fermented by yogurt cultures plus Lactobacillus casei DN-114001 on the immune response of subjects under academic examination stress. Eur J Nutr. 2004 Dec;43(6):381-9. Epub 2004 Jul 14.</citation>
    <PMID>15309418</PMID>
  </reference>
  <reference>
    <citation>Marin IA, Goertz JE, Ren T, Rich SS, Onengut-Gumuscu S, Farber E, Wu M, Overall CC, Kipnis J, Gaultier A. Microbiota alteration is associated with the development of stress-induced despair behavior. Sci Rep. 2017 Mar 7;7:43859. doi: 10.1038/srep43859.</citation>
    <PMID>28266612</PMID>
  </reference>
  <reference>
    <citation>Mason JW. A review of psychoendocrine research on the pituitary-adrenal cortical system. Psychosom Med. 1968 Sep-Oct;30(5):Suppl:576-607. Review.</citation>
    <PMID>4303377</PMID>
  </reference>
  <reference>
    <citation>Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, Bisson JF, Rougeot C, Pichelin M, Cazaubiel M, Cazaubiel JM. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011 Mar;105(5):755-64. doi: 10.1017/S0007114510004319. Epub 2010 Oct 26.</citation>
    <PMID>20974015</PMID>
  </reference>
  <reference>
    <citation>Nater UM, La Marca R, Florin L, Moses A, Langhans W, Koller MM, Ehlert U. Stress-induced changes in human salivary alpha-amylase activity -- associations with adrenergic activity. Psychoneuroendocrinology. 2006 Jan;31(1):49-58. Epub 2005 Jul 5.</citation>
    <PMID>16002223</PMID>
  </reference>
  <reference>
    <citation>Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil. 2011 Mar;23(3):255-64, e119. doi: 10.1111/j.1365-2982.2010.01620.x. Epub 2010 Nov 5.</citation>
    <PMID>21054680</PMID>
  </reference>
  <reference>
    <citation>Nishida, K., Sawada, D., Kuwano, Y., Tanaka, H., Sugawara, T., Aoki, Y., ... &amp; Rokutan, K. (2017). Daily administration of paraprobiotic lactobacillus gasseri cp2305 ameliorates chronic stress-associated symptoms in Japanese medical students. Journal of Functional Foods, 36, 112-121.</citation>
  </reference>
  <reference>
    <citation>O'Mahony SM, Marchesi JR, Scully P, Codling C, Ceolho AM, Quigley EM, Cryan JF, Dinan TG. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry. 2009 Feb 1;65(3):263-7. doi: 10.1016/j.biopsych.2008.06.026. Epub 2008 Aug 23.</citation>
    <PMID>18723164</PMID>
  </reference>
  <reference>
    <citation>O'Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015 Jan 15;277:32-48. doi: 10.1016/j.bbr.2014.07.027. Epub 2014 Jul 29. Review.</citation>
    <PMID>25078296</PMID>
  </reference>
  <reference>
    <citation>Ogbonnaya ES, Clarke G, Shanahan F, Dinan TG, Cryan JF, O'Leary OF. Adult Hippocampal Neurogenesis Is Regulated by the Microbiome. Biol Psychiatry. 2015 Aug 15;78(4):e7-9. doi: 10.1016/j.biopsych.2014.12.023. Epub 2015 Jan 9.</citation>
    <PMID>25700599</PMID>
  </reference>
  <reference>
    <citation>De Palma G, Collins SM, Bercik P, Verdu EF. The microbiota-gut-brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both? J Physiol. 2014 Jul 15;592(14):2989-97. doi: 10.1113/jphysiol.2014.273995. Epub 2014 Apr 22. Review.</citation>
    <PMID>24756641</PMID>
  </reference>
  <reference>
    <citation>Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, Martin FP, Cominetti O, Welsh C, Rieder A, Traynor J, Gregory C, De Palma G, Pigrau M, Ford AC, Macri J, Berger B, Bergonzelli G, Surette MG, Collins SM, Moayyedi P, Bercik P. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017 Aug;153(2):448-459.e8. doi: 10.1053/j.gastro.2017.05.003. Epub 2017 May 5.</citation>
    <PMID>28483500</PMID>
  </reference>
  <reference>
    <citation>Sherwin E, Rea K, Dinan TG, Cryan JF. A gut (microbiome) feeling about the brain. Curr Opin Gastroenterol. 2016 Mar;32(2):96-102. doi: 10.1097/MOG.0000000000000244. Review.</citation>
    <PMID>26760398</PMID>
  </reference>
  <reference>
    <citation>Sherwin E, Sandhu KV, Dinan TG, Cryan JF. May the Force Be With You: The Light and Dark Sides of the Microbiota-Gut-Brain Axis in Neuropsychiatry. CNS Drugs. 2016 Nov;30(11):1019-1041. Review.</citation>
    <PMID>27417321</PMID>
  </reference>
  <reference>
    <citation>Slykerman RF, Hood F, Wickens K, Thompson JMD, Barthow C, Murphy R, Kang J, Rowden J, Stone P, Crane J, Stanley T, Abels P, Purdie G, Maude R, Mitchell EA; Probiotic in Pregnancy Study Group. Effect of Lactobacillus rhamnosus HN001 in Pregnancy on Postpartum Symptoms of Depression and Anxiety: A Randomised Double-blind Placebo-controlled Trial. EBioMedicine. 2017 Oct;24:159-165. doi: 10.1016/j.ebiom.2017.09.013. Epub 2017 Sep 14.</citation>
    <PMID>28943228</PMID>
  </reference>
  <reference>
    <citation>Steenbergen L, Sellaro R, van Hemert S, Bosch JA, Colzato LS. A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain Behav Immun. 2015 Aug;48:258-64. doi: 10.1016/j.bbi.2015.04.003. Epub 2015 Apr 7.</citation>
    <PMID>25862297</PMID>
  </reference>
  <reference>
    <citation>Stilling RM, Ryan FJ, Hoban AE, Shanahan F, Clarke G, Claesson MJ, Dinan TG, Cryan JF. Microbes &amp; neurodevelopment--Absence of microbiota during early life increases activity-related transcriptional pathways in the amygdala. Brain Behav Immun. 2015 Nov;50:209-220. doi: 10.1016/j.bbi.2015.07.009. Epub 2015 Jul 14.</citation>
    <PMID>26184083</PMID>
  </reference>
  <reference>
    <citation>Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004 Jul 1;558(Pt 1):263-75. Epub 2004 May 7.</citation>
    <PMID>15133062</PMID>
  </reference>
  <reference>
    <citation>Takada M, Nishida K, Kataoka-Kato A, Gondo Y, Ishikawa H, Suda K, Kawai M, Hoshi R, Watanabe O, Igarashi T, Kuwano Y, Miyazaki K, Rokutan K. Probiotic Lactobacillus casei strain Shirota relieves stress-associated symptoms by modulating the gut-brain interaction in human and animal models. Neurogastroenterol Motil. 2016 Jul;28(7):1027-36. doi: 10.1111/nmo.12804. Epub 2016 Feb 20.</citation>
    <PMID>26896291</PMID>
  </reference>
  <reference>
    <citation>Takai N, Yamaguchi M, Aragaki T, Eto K, Uchihashi K, Nishikawa Y. Effect of psychological stress on the salivary cortisol and amylase levels in healthy young adults. Arch Oral Biol. 2004 Dec;49(12):963-8.</citation>
    <PMID>15485637</PMID>
  </reference>
  <reference>
    <citation>Tannock GW, Savage DC. Influences of dietary and environmental stress on microbial populations in the murine gastrointestinal tract. Infect Immun. 1974 Mar;9(3):591-8.</citation>
    <PMID>4593471</PMID>
  </reference>
  <reference>
    <citation>Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, Guyonnet D, Legrain-Raspaud S, Trotin B, Naliboff B, Mayer EA. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013 Jun;144(7):1394-401, 1401.e1-4. doi: 10.1053/j.gastro.2013.02.043. Epub 2013 Mar 6.</citation>
    <PMID>23474283</PMID>
  </reference>
  <reference>
    <citation>Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 2002 Oct;53(4):865-71. Review.</citation>
    <PMID>12377295</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Daacro</investigator_affiliation>
    <investigator_full_name>Juliane Hellhammer</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <keyword>Gut-brain axis</keyword>
  <keyword>Stress</keyword>
  <keyword>Anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

